2seventy bio finalizes $40m haemophilia A deal with Novo Nordisk

US-based biotechnology company 2seventy bio has finalized an asset purchase agreement (APA) to transfer its haemophilia A candidate to Novo Nordisk. This strategic move marks the conclusion of a collaborative research agreement that the two companies initiated in 2019, aimed at developing a gene editing therapy specifically for individuals suffering from haemophilia A.

Haemophilia A is a rare genetic disorder characterized by the inability of blood to clot normally due to a deficiency in specific blood-clotting proteins. This condition can lead to severe bleeding episodes, which can be life-threatening if not properly managed.

Under the terms of the APA, 2seventy bio stands to receive up to $40 million. In addition, Novo Nordisk will acquire rights to 2seventy bio’s MegaTAL in vivo gene editing technology, which can be applied to projects outside the realms of oncology and autoimmune disorders. This technology transfer is expected to bolster Novo Nordisk's portfolio and enhance their capability to develop advanced gene therapies.

As part of the transition, team members from 2seventy bio who have been involved in the haemophilia A program will join Novo Nordisk to continue the development of the technology. This move ensures a seamless continuation of the research and development efforts.

2seventy bio CEO Chip Baird expressed his optimism about the transition: “Novo Nordisk has been a valued partner over the past five years, and we are confident that under their leadership, the promise of developing a new treatment approach for patients living with haemophilia A will continue to progress.” Baird’s comments reflect the strong partnership between the two companies and the shared commitment to advancing medical treatments for haemophilia A.

Moving forward, 2seventy bio intends to sharpen its focus on the development and commercialization of Abecma (idecabtagene vicleucel), its BCMA-targeted chimeric antigen receptor (CAR)-T cell therapy designed for treating multiple myeloma (MM). This therapy was developed in collaboration with Bristol Myers Squibb (BMS). Abecma received approval from the US Food and Drug Administration (FDA) in April 2024, marking a significant milestone for the company.

Despite some recent controversies surrounding the safety of CAR-T therapies, an FDA committee voted eight to three in favor of approving Abecma. This decision underscores the potential benefits and therapeutic value that Abecma offers to patients with multiple myeloma, a type of cancer that forms in plasma cells.

With this strategic refocus, 2seventy bio aims to leverage its expertise and resources to push the boundaries of CAR-T cell therapy, potentially offering new hope to patients battling multiple myeloma. The company’s concerted efforts in this area reflect its commitment to advancing innovative treatments and improving patient outcomes.